当部案内
技術支援室
技術支援室では、臨床研究等で得られた貴重な検体の処理及び保管管理、並びに当該検体を利用した新たな研究企画及び実施をしております。
連携機関
スタッフ紹介
更新日:2022年12月15日
役職 | 名前 |
技術支援室室長(併任) | 木村 基, Moto KIMURA |
上級研究員 | 竹内(柴田)潤子, Junko S. TAKEUCHI |
上級研究員 | 深野 顕人, Kento FUKANO |
特任研究員 | 神川 あずさ, Azusa KAMIKAWA |
特任研究員 | 鬼頭 優美子, Yumiko KITO |
研究補助員 | 有吉 希, Nozomi ARIYOSHI |
研究補助員 | 波田野 恵美子, Emiko HATANO |
研究補助員 | 髙橋 杏奈, Anna TAKAHASHI |
事務助手 | 田村 良子, Ryoko TAMURA |
実績
出版論文(技術支援室発足以降)
出版論文(査読付論文誌)
-
[1] Neutralizing antibodies following three doses of BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron predominant wave.
Yamamoto, S., K. Matsuda, K. Maeda, K. Horii, K. Okudera, Y. Oshiro, N. Inamura, J. S. Takeuchi, M. Konishi, M. Ozeki, T. Mizoue, H. Sugiyama, N. Aoyanagi, H. Mitsuya, W. Sugiura, and N. Ohmagari. 2023.
Int J Infect Dis. 2023 Jan 21 : S1201-9712(23)00023-1.
https://doi.org/10.1016/j.ijid.2023.01.023. -
[2] SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study.
Takeuchi, J. S., A. Fukunaga, S. Yamamoto, A. Tanaka, K. Matsuda, M. Kimura, A. Kamikawa, Y. Kito, K. Maeda, G. Ueda, T. Mizoue, M. Ujiie, H. Mitsuya, N. Ohmagari, and W. Sugiura (2022).
Scientific Reports 12 (1): 15447.
https://doi.org/10.1038/s41598-022-19581-y -
[3] Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination.
Okumura, N., S. Saito, Y. Takamatsu, J. S. Takeuchi, Y. Asai, M. Sanada, N. Iwamoto, K. Maeda, H. Mitsuya, and N. Ohmagari (2022).
J Infect Chemother 28 (12): 1704-1706.
https://doi.org/10.1016/j.jiac.2022.08.026 -
[4] Protocol of an Exploratory Single-Arm Study to Evaluate the Safety and Immunogenicity of KD-414 as a Booster Vaccine for SARS-CoV-2 in Healthy Adults (KAPIVARA).
Terayama, Y., N. Tomita, J. Terada-Hirashima, Y. Uemura, Y. Shimizu, J. S. Takeuchi, Y. Takamatsu, K. Maeda, A. Mikami, M. Ujiie, and W. Sugiura (2022).
Life (Basel) 12 (7).
https://doi.org/10.3390/life12070966 -
[5] Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan.
Okumura, N., S. Tsuzuki, S. Saito, S. I. Hattori, J. S. Takeuchi, T. Saito, M. Ujiie, M. Hojo, N. Iwamoto, W. Sugiura, H. Mitsuya, and N. Ohmagari (2022).
J Infect Chemother 28 (9): 1340-1343.
https://doi.org/10.1016/j.jiac.2022.04.018 -
[6] An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine.
Khor, S. S., Y. Omae, J. S. Takeuchi, A. Fukunaga, S. Yamamoto, A. Tanaka, K. Matsuda, M. Kimura, K. Maeda, G. Ueda, T. Mizoue, M. Ujiie, H. Mitsuya, N. Ohmagari, W. Sugiura, and K. Tokunaga (2022).
Vaccines (Basel) 10 (4).
https://doi.org/10.3390/vaccines10040563 -
[7] Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
Miyazato, Y., K. Yamamoto, Y. Nakaya, S. Morioka, J. S. Takeuchi, Y. Takamatsu, K. Maeda, M. Kimura, W. Sugiura, H. Mitsuya, M. Yano, and N. Ohmagari (2022).
J Infect Chemother 28 (7): 991-994.
https://doi.org/10.1016/j.jiac.2022.03.002 -
[8] Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
Yamamoto, S., A. Fukunaga, A. Tanaka, J. S. Takeuchi, Y. Inoue, M. Kimura, K. Maeda, G. Ueda, T. Mizoue, M. Ujiie, W. Sugiura, and N. Ohmagari (2022.)
Vaccine 40 (13): 1924-1927.
https://doi.org/10.1016/j.vaccine.2022.02.052 -
[9] Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study.
Yamamoto, S., K. Maeda, K. Matsuda, A. Tanaka, K. Horii, K. Okudera, J. S. Takeuchi, T. Mizoue, M. Konishi, M. Ozeki, H. Sugiyama, N. Aoyanagi, H. Mitsuya, W. Sugiura, and N. Ohmagari (2022).
Clin Infect Dis 75 (1): e683-e691.
https://doi.org/10.1093/cid/ciab1048
preprint
-
[1]SARS-CoV-2 breakthrough infection during the Delta-dominant epidemic and neutralizing antibodies against Omicron in comparison with the third dose of BNT162b2: a matched analysis.
Yamamoto, S., K. Matsuda, K. Maeda, Y. Oshiro, N. Inamura, T. Mizoue, M. Konishi, J. S. Takeuchi, K. Horii, M. Ozeki, H. Sugiyama, H. Mitsuya, W. Sugiura and N. Ohmagari (2022).
https://doi.org/10.1101/2022.06.21.22276682
https://www.medrxiv.org/content/10.1101/2022.06.21.22276682v1
お問い合せ
臨床研究センター 産学連携推進部
技術支援室:
REBIND事業事務局: